Search results for "Isoquinoline"

showing 10 items of 178 documents

CCDC 2070166: Experimental Crystal Structure Determination

2021

Related Article: Shrabani Saha, Sujoy Das, Olivia Sarkar, Ansuman Chattopadhyay, Kari Rissanen, Prithidipa Sahoo|2021|New J.Chem.|45|17095|doi:10.1039/D1NJ02661E

2-(9-ethyl-9H-carbazol-3-yl)-1H-benzo[de]isoquinoline-13(2H)-dioneSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 916245: Experimental Crystal Structure Determination

2013

Related Article: Santos Fustero, Ignacio Ibáñez, Pablo Barrio, Miguel A. Maestro, Silvia Catalán|2013|Org.Lett.|15|832|doi:10.1021/ol3035142

3-(4-Methoxyphenyl)-1-(trifluoromethyl)-1234-tetrahydroisoquinolineSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

N-SUBSTITUTION AND á1-ADRENERGIC RECEPTOR AFFINITY OF LAUDANOSINE ANALOGUES

2006

Benzyltetrahydroisoquinoline (BTHIQ) molecules are able to adopt widely differing conformations that depend on the presence or absence of N-substituents. To assess the possible role of BTHIQ conformation on the affinity of these compounds for α 1 -adrenergic receptors, of interest for the management of hypertension, the racemic N-unsubstituted BTHIQ norlaudanosine and a series of N-alkylated derivatives were assessed for binding to rat brain cortical sites labelled with the radioligand [3H]prazosin. The α 1 -adrenergic affinity in this series increased with the bulk of the substituent on the nitrogen atom, from the N-ethyl to the N-propyl analogue. Comparison of these results with published…

Adrenergic receptorStereochemistrylaudanosineSubstituentAdrenergicGeneral ChemistryAdrenergic receptor bindinga 1-adrenergic receptor bindingGlaucineglaucineLaudanosinebenzyltetrahydroisoquinolineschemistry.chemical_compoundchemistrytetrahydropalmatineN-alkylnorlaudanosinesRadioligandPrazosinmedicinenorlaudanosinemedicine.drugJournal of the Chilean Chemical Society
researchProduct

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

2015

ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

AdultLiver CirrhosisMaleDaclatasvirPyrrolidinesAlpha interferonHIV InfectionsHepacivirusPharmacologyAntiviral AgentsRaltegravir PotassiumPolyethylene Glycolschemistry.chemical_compoundPharmacokineticsRaltegravir PotassiumRibavirinMedicineHumansPharmacology (medical)PharmacologySulfonamidesbusiness.industryCoinfectionRibavirinImidazolesvirus diseasesInterferon-alphaValineHepatitis CHepatitis C ChronicMiddle AgedRaltegravirmedicine.diseaseIsoquinolinesdigestive system diseasesRecombinant ProteinsInfectious DiseaseschemistryLiverHIV-1AsunaprevirDrug Therapy CombinationFemaleCarbamatesbusinessmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lym…

2011

Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), i.e. CPOP (cyclophosphamide, pixantrone, vincristine, and prednisone), in patients with relapsed aNHL who had previously received CHOP ± rituximab. Patients were administered pixantrone on day 1 of each 21-day cycle. Phase I (n = 35) dose escalation from 80 mg/m(2) to 180 mg/m(2) established the phase II (n = 30) dose as 150 mg/m(2). In phase II, 20 patients (67%) received all…

AdultMaleCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidePhases of clinical researchAntineoplastic AgentsPharmacologyGastroenterologychemistry.chemical_compoundPrednisoneRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedNeoplasm StagingAged 80 and overPixantronebusiness.industryLymphoma Non-HodgkinHematologyMiddle Agedmedicine.diseaseIsoquinolinesSurvival AnalysisTreatment OutcomeOncologychemistryVincristinePrednisoneMantle cell lymphomaFemalebusinessDiffuse large B-cell lymphomaFebrile neutropeniaImmunosuppressive Agentsmedicine.drugLeukemialymphoma
researchProduct

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin

2017

<b><i>Objectives:</i></b> Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role of BMI as a risk factor for trabectedin-related toxicity in patients with STS. <b><i>Methods:</i></b> Data from 51 patients with metastatic/advanced STS treated with trabectedin after progression on ≥1 anthracycline ± ifosfamide regimen were retrospe…

AdultMaleOncologySarcopeniaCancer Researchmedicine.medical_specialtyNeutropeniaDioxolesNeutropeniaBody Mass Index03 medical and health sciences0302 clinical medicineThinnessRisk FactorsTetrahydroisoquinolinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesIfosfamide030212 general & internal medicineRisk factorAntineoplastic Agents AlkylatingTrabectedinAgedRetrospective StudiesAged 80 and overIfosfamideToxicitybusiness.industrySoft tissue sarcomanutritional and metabolic diseasesSarcomaGeneral MedicineMiddle Agedmedicine.diseaseOncology030220 oncology & carcinogenesisSoft-tissue sarcomaFemaleUnderweightmedicine.symptombusinessBody mass indexFebrile neutropeniaTrabectedinmedicine.drugOncology
researchProduct

The 5-HT and alpha-adrenoceptor antagonist effect of four benzylisoquinoline alkaloids on rat aorta.

1998

Abstract The action of four benzylisoquinoline alkaloids (two aporphines—glaucine and apomorphine, a benzylisoquinoline—papaverine and a bisbenzyltetrahydroisoquinoline—antioquine) on 5-HT-induced contraction in rat thoracic aorta has been examined and compared with that of the control drugs: ketanserin, nifedipine, prazosin and phentolamine. The relaxant action on 5-HT-induced contraction was contrasted with that on the contraction induced by noradrenaline and KCl. The results obtained with control drugs show that ketanserin has clear selectivity for 5-HT receptors, whereas prazosin and phentolamine have high selectivity for the α1-adrenoceptor and nifedipine seems to have a more potent ef…

AgonistMalemedicine.medical_specialtySerotoninKetanserinAporphinesApomorphinemedicine.drug_classPharmaceutical ScienceAorta ThoracicIn Vitro TechniquesBenzylisoquinolinesMuscle Smooth Vascularchemistry.chemical_compoundPhentolamineAlkaloidsInternal medicinePapaverinemedicinePrazosinAnimalsRats WistarBenzylisoquinolineAdrenergic alpha-AntagonistsPharmacologyPapaverineDose-Response Relationship DrugChemistryParasympatholyticsCalcium Channel BlockersIsoquinolinesGlaucineRatsApomorphineEndocrinologyDopamine Agonistsmedicine.drugMuscle ContractionThe Journal of pharmacy and pharmacology
researchProduct

A Highly Active System for the Metal-Free Aerobic Photocyanation of Tertiary Amines with Visible Light: Application to the Synthesis of Tetraponerine…

2015

A highly efficient metal-free catalytic system for the aerobic photocyanation of tertiary amines with visible light is reported. The use of air as terminal oxidant offers an improved safety profile compared with pure oxygen, the used compact fluorescent lamp (CFL) light sources are highly economical, and no halogenated solvents are required. This system not only proves to be effective for a wide variety of trialkylamines, pharmaceuticals, and alkaloids but remarkably also allows the lowest catalyst loading (0.00001 mol% or 0.1 ppm) ever reported for an organic dye. Bruylants reactions and C-alkylation/decyanations were performed on the obtained α-aminonitriles to demonstrate the postfunctio…

AlkylationLightMolecular Structure010405 organic chemistryChemistryOrganic ChemistryTotal synthesisActive systemsGeneral ChemistryAlkylationIsoquinolines010402 general chemistry01 natural sciencesCatalysis0104 chemical sciencesCatalysisAlkaloidsMetal freeMetalsPhotocatalysisOrganic chemistryMoleculeAminesOxidation-ReductionVisible spectrumChemistry - A European Journal
researchProduct

Synthesis and conformational analysis of tetrahydroisoquinoline- and piperidine-fused 1,3,4,2-oxadiazaphosphinanes, new ring systems

2006

Abstract Through cyclization of tetrahydroisoquinoline and piperidine 1,2-hydrazino alcohols with phenylphosphonic dichloride and phenyl dichlorophosphate, P-epimeric diastereomers of 1,6,7,11b-tetrahydro-4H-1,3,4,2-oxadiazaphosphino[5,4-a]isoquinoline-3-oxides ( 13 and 14 ), 1,6,11,11a-tetrahydro-4H-1,3,4,2-oxadiazaphosphino[4,5-b]isoquinoline-3-oxides ( 15 and 16 ) and 1,6,7,8,9,9a-hexahydro-4H-pyrido[1,2-d][1,3,4,2]oxadiazaphosphinane-3-oxides ( 17 and 18 ), the first representatives of these ring systems, were prepared. NMR and X-ray diffraction studies revealed that, independently of the P-substituent and the relative configuration of the phosphorus atom, 13 , 14 , 17 and 18 could be c…

AnnulationStereochemistryTetrahydroisoquinolineOrganic ChemistryCyclohexane conformationDiastereomerRing (chemistry)Biochemistrychemistry.chemical_compoundchemistryDrug DiscoveryMoietyPiperidinePhenyl dichlorophosphateTetrahedron
researchProduct

Novel isoquinoline derivatives as antimicrobial agents.

2013

The wide variety of potent biological activities of natural and synthetic isoquinoline alkaloids encouraged us to develop novel antimicrobial isoquinoline compounds. We synthesized a variety of differently functionalized 1-pentyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolines (THIQs), including dihydroisoquinolinium salts (2 and 5), methyl pentanoate-THIQ (6), 1-pentanol-THIQ (7), ester derivatives (8-15) and carbamate derivatives (16-23). We employed classic intramolecular Bischler-Napieralski cyclodehydration to generate the isoquinoline core. All the structures were characterized by nuclear magnetic resonance and mass spectrometry. The bactericide and fungicide activities were evaluated f…

AntifungalCarbamateAntifungal Agentsmedicine.drug_classmedicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceMicrobial Sensitivity TestsGram-Positive BacteriaBiochemistrychemistry.chemical_compoundStructure-Activity RelationshipAnti-Infective AgentsDrug DiscoveryGram-Negative BacteriamedicineOrganic chemistryStructure–activity relationshipIsoquinolineMolecular BiologyEster derivativesChemistryOrganic ChemistryFungiAntimicrobialIsoquinolinesAnti-Bacterial AgentsIntramolecular forceMolecular MedicineBioorganicmedicinal chemistry
researchProduct